Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Alcoholic Liver Disease Human Serum Proteomics

ABSTRACT: Alcoholic liver disease LC-MS/MS quantitative proteomics with top14 abundant protein depletion

ORGANISM(S): Homo Sapiens

SUBMITTER: Chengbin Wang

PROVIDER: PXD036941 | iProX | Thu Sep 22 00:00:00 BST 2022

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

Novel potential biomarkers for severe alcoholic liver disease.

Huang Jia J Yu Jiachi J Wang Jianan J Liu Jiayu J Xie Wei W Li Ruibing R Wang Chengbin C

Frontiers in immunology 20221213

<h4>Background</h4>Alcoholic liver disease (ALD) is a leading cause of advanced liver disease; however, minor clinical symptoms in the early stage frequently result in delayed diagnosis and therapy. Invasive liver biopsy, the gold standard for diagnosing ALD, is unsuitable for repetitive analysis. This study aims to identify potential serum biomarkers that could contribute to non-invasive disease screening and monitoring.<h4>Methods</h4>Label-free LC-MS/MS quantitative proteomics analysis was pe ...[more]

PMID: 36582223

Similar Datasets

Liver proteomics for alcoholic liver disease

Project description:LC-MS/MS quantitative liver proteomics for alcoholic liver disease

2024-11-28 | PXD058395 |

Expression data from human non-alcoholic fatty liver disease stages

Project description:Global gene expression patterns of 2 human steatosis and 9 human non-alcoholic steatohepatitis (NASH) together with their respective control patterns were analyzed to define the non-alcoholic fatty liver disease (NAFLD) progression molecular characteristics and to define NASH early markers from steatosis. Human liver samples of steatosis and non-alcoholic steatohepatitis were selected for RNA extraction and hybridization on Affymetrix microarrays. This dataset is part of the TransQST collection.

2014-11-07 | E-GEOD-63067 | biostudies-arrayexpress

Expression data from human non-alcoholic fatty liver disease stages

2014-11-07 | GSE63067 | GEO

Microbiome in Alcoholic Liver Disease

Project description:The Role of the Microbiome in Alcoholic Liver Disease

| PRJEB14784 | ENA

The RNA-seq data in riboflavin-treated alcoholic liver disease

Project description:Alcoholic liver disease (ALD) is a kind serious liver disease, which will develope into the cirrhosis, liver cancer and so on. The study results show that riboflavin has the protective effect against ALD. Then the study divides the C57BL/6 mice into the three groups that were Control (C), Alcohol, Alcohol with riboflavin (AR) groups respectively. And the study makes the mouse liver RNA sequencing (RNA-seq) to find the differential expression mRNAs among three groups futher and does the related analysis in riboflavin-treated alcoholic liver disease.

2024-08-28 | GSE273208 | GEO

High Density Lipoprotein Proteome in Non-alcoholic Fatty Liver Disease Patients

Project description:Characterization of HDL proteome in patients diagnosed with non-alcoholic fatty liver disease and to evaluate the impact on HDL function.

2018-09-13 | PXD005847 | Pride

Transcriptome profiling of human non-alcoholic fatty liver disease

Project description:Transcriptome profiling of human non-alcoholic fatty liver disease

| PRJNA704861 | ENA

The 16S RNA-seq data in riboflavin-treated alcoholic liver disease

Project description:Alcoholic liver disease (ALD) is a kind of liver disease that will result in liver cancer and some other high death rate liver disease. The study results show that riboflavin could protect the mouse against ALD. Then the study divides the C57BL/6 mice into the three groups including Control (C), Alcohol, Alcohol with riboflavin (AR) groups respectively. And the study makes the mouse stool samples 16S RNA sequencing (RNA-seq) to find the differential itestinal microbiota homeostasis among three groups futher and does the related analysis in riboflavin-treated alcoholic liver disease.

2024-08-28 | GSE273370 | GEO

MicroRNA expression profile in non-alcoholic fatty liver disease

Project description:Simple steatosis (SS) and non-alcoholic steatohepatitis (NASH) are subtypes of non-alcoholic fatty liver disease. The difference in pathogenesis between SS and NASH is still not clear. MicroRNAs (miRNAs) are endogenous, non-coding short RNAs that regulate gene expression. The aim of this study was to examine the relationship of miRNA expression profiles with SS and NASH in animal models and humans.

2016-01-01 | GSE69670 | GEO

XCR1+ type 1 conventional dendritic cells drive liver pathology in Non-Alcoholic Steatohepatitis [scRNA-seq]

Project description:Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are prevalent liver conditions, which underlie the development of life-threatening cirrhosis, liver failure and liver cancer. Chronic necro-inflammation is a critical factor in development of NASH, yet the cellular and molecular mechanisms of immune dysregulation in this disease are poorly understood. Here, using single cell transcriptomic analysis, we comprehensively profiled the immune composition of the mouse liver during NASH. We identified a significant pathology-associated increase in hepatic conventional dendritic cells (cDC), and further defined their source as NASH-induced boost in cycling of cDC progenitors in the bone marrow. Analysis of blood and liver from patients on the NALFD/NASH spectrum showed that cDC type 1 (cDC1) were more abundant and activated in disease. Genomic analysis of cDC-T pairs in liver draining lymph nodes revealed that cDCs in NASH promote inflammatory T cell reprogramming, previously associated with NASH worsening. Finally, depletion of cDC1 in XCR1DTA mice or using anti-XCL1 blocking antibody attenuated liver pathology in NASH mouse models. Overall, our study provides a comprehensive characterization of cDC biology in NASH, and identifies XCR1+ cDC1 as an important driver of liver pathology.

2021-05-21 | GSE169445 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data